The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

HORSHAM, Pa., July 11, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

The findings showed no significant differences between the treatment and benzoyl peroxide, and they suggest that intense pulse light is both effective and well tolerated among patients. A pair of ...

Choosing the best treatments for acne The disfiguring lesions of acne vulgaris can have a severe psychological impact. Fortunately, clinicians now have a broad range of therapeutic options. Acne ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A multi-center, prospective, open-label, single arm ...

Acne vulgaris is a chronic inflammatory skin condition that primarily affects the pilosebaceous unit, leading to the development of non-inflammatory lesions such as comedones and inflammatory lesions ...

The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020. The first-in-class ...

Clinically, acne presentation differs based on condition severity. Mild acne is typically localized to the face and manifests as noninflammatory open and closed comedones. 2 Moderate presentations of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. By week 24, the number of lesions decreased by 53% from ...

LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene ...